NRIX Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

7 days ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

11 days ago - By: Benzinga

13 Analysts Have This To Say About Nurix Therapeutics

11 days ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

19 days ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

a month ago - By: Benzinga

Breaking Down Nurix Therapeutics: 5 Analysts Share Their Views

a month ago - By: Stocktwits

Nurix Stock Falls After-Hours After Wider Q3 Loss; Oppenheimer Sees FDA Support For Bexo, Retail Buys The Dip

24 days ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock

24 days ago - By: Nurix Therapeutics, Inc.

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

a month ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

6 months ago - By: Nurix Therapeutics, Inc.

Sanofi Exercises License Extension Option to Nurix’s STAT6 Program

a month ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

2 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

3 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics to Participate in Upcoming Investor Conferences

4 months ago - By: Stocktwits - Mentions: GILD

Nurix Therapeutics Posts Better-Than-Expected Q2 Results; Revenue Soars on Sanofi and Gilead Payments

4 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

5 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström

5 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

6 months ago - By: Yahoo Finance - Mentions: SNY BPMC VZ DHI ...

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout

6 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

6 months ago - By: Yahoo Finance - Mentions: DHI CMG

NURIX THERAPEUTICS INC (NRIX) Stock News

NRIX Latest News, Press Relases and Analysis

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

13 Analysts Have This To Say About Nurix Therapeutics

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

Breaking Down Nurix Therapeutics: 5 Analysts Share Their Views

Nurix Stock Falls After-Hours After Wider Q3 Loss; Oppenheimer Sees FDA Support For Bexo, Retail Buys The Dip

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

Sanofi Exercises License Extension Option to Nurix’s STAT6 Program

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics Posts Better-Than-Expected Q2 Results; Revenue Soars on Sanofi and Gilead Payments

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

Why Nurix Therapeutics (NRIX) Is Among the Best Low Priced Biotech Stocks to Buy Now